AS
Altshuler Shaham Portfolio holdings
AUM
$3.14B
1-Year Return
24.55%
This Quarter Return
+0.13%
1 Year Return
+24.55%
3 Year Return
+51.84%
5 Year Return
+71.45%
10 Year Return
–
AUM
$2.38B
AUM Growth
+$188M
(+8.6%)
Cap. Flow
+$184M
Cap. Flow
% of AUM
7.72%
Top 10 Holdings %
Top 10 Hldgs %
79.65%
Holding
420
New
125
Increased
152
Reduced
62
Closed
60
Top Buys
| 1 |
Cisco
CSCO
|
$62.8M |
| 2 |
Palo Alto Networks
PANW
|
$45.1M |
| 3 |
Fortinet
FTNT
|
$33.4M |
| 4 |
Check Point Software Technologies
CHKP
|
$30.7M |
| 5 |
iShares MSCI South Korea ETF
EWY
|
$30M |
Top Sells
| 1 |
Builders FirstSource
BLDR
|
$29.5M |
| 2 |
Alibaba
BABA
|
$27.1M |
| 3 |
ICL Group
ICL
|
$9.98M |
| 4 |
Elbit Systems
ESLT
|
$3.97M |
| 5 |
International Flavors & Fragrances
IFF
|
$2.06M |
Sector Composition
| 1 | Technology | 31.7% |
| 2 | Consumer Discretionary | 16.23% |
| 3 | Industrials | 7.87% |
| 4 | Real Estate | 4.08% |
| 5 | Healthcare | 1.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
The Ensign Group
ENSG
$10B
| $11K | ﹤0.01% |
203
+29
| +17% | +$1.57K |
|
277
Edwards Lifesciences
EW
$47.5B
| $11K | ﹤0.01% |
177
-150
| -46% | -$9.32K |
|
278
Exelixis
EXEL
$10.2B
| $11K | ﹤0.01% |
+497
| New | +$11K |
|
279
Hologic
HOLX
$14.8B
| $11K | ﹤0.01% |
226
+58
| +35% | +$2.82K |
|
280
Henry Schein
HSIC
$8.42B
| $11K | ﹤0.01% |
153
+16
| +12% | +$1.15K |
|
281
Incyte
INCY
$16.9B
| $11K | ﹤0.01% |
125
-101
| -45% | -$8.89K |
|
282
Johnson & Johnson
JNJ
$430B
| $11K | ﹤0.01% |
76
-59
| -44% | -$8.54K |
|
283
Medtronic
MDT
$119B
| $11K | ﹤0.01% |
108
+22
| +26% | +$2.24K |
|
284
Omnicell
OMCL
$1.47B
| $11K | ﹤0.01% |
125
-102
| -45% | -$8.98K |
|
285
Insulet
PODD
$24.5B
| $11K | ﹤0.01% |
+91
| New | +$11K |
|
286
Qiagen
QGEN
$10.3B
| $11K | ﹤0.01% |
251
+61
| +32% | +$2.67K |
|
287
Stryker
SYK
$150B
| $11K | ﹤0.01% |
55
-45
| -45% | -$9K |
|
288
Thermo Fisher Scientific
TMO
$186B
| $11K | ﹤0.01% |
38
+7
| +23% | +$2.03K |
|
289
West Pharmaceutical
WST
$18B
| $11K | ﹤0.01% |
+88
| New | +$11K |
|
|
PDCO
290
DELISTED
Patterson Companies, Inc.
PDCO
| $11K | ﹤0.01% |
462
+100
| +28% | +$2.38K |
|
|
HRC
291
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $11K | ﹤0.01% |
101
-80
| -44% | -$8.71K |
|
|
INOV
292
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $11K | ﹤0.01% |
+724
| New | +$11K |
|
293
AbbVie
ABBV
$375B
| $10K | ﹤0.01% |
+133
| New | +$10K |
|
294
Herbalife
HLF
$1.02B
| $10K | ﹤0.01% |
235
+96
| +69% | +$4.09K |
|
295
Ionis Pharmaceuticals
IONS
$9.76B
| $10K | ﹤0.01% |
155
+42
| +37% | +$2.71K |
|
296
OrthoPediatrics
KIDS
$524M
| $10K | ﹤0.01% |
+254
| New | +$10K |
|
297
Eli Lilly
LLY
$652B
| $10K | ﹤0.01% |
87
-61
| -41% | -$7.01K |
|
298
NeoGenomics
NEO
$1.03B
| $10K | ﹤0.01% |
452
+32
| +8% | +$708 |
|
299
Bio-Techne
TECH
$8.46B
| $10K | ﹤0.01% |
200
+36
| +22% | +$1.8K |
|
300
Zimmer Biomet
ZBH
$20.9B
| $10K | ﹤0.01% |
+90
| New | +$10K |
|